IGF-1 LR3: the complete research guide.

IGF-1 LR3 is the most pro-growth version of this hormone family a chemist can build. Long-lasting. Almost no buffering by the body's normal carrier proteins. Direct, sustained signaling on a pathway that, in large population studies, tracks with cancer incidence. The published preclinical literature, regulatory status, and central cancer-biology concern are reviewed below.

What is IGF-1 LR3?

LR3 is a synthetic 83-amino-acid version of human insulin-like growth factor 1, a hormone the liver produces in response to growth hormone signaling. The natural version is 70 amino acids. LR3 incorporates two structural modifications:

• A 13-amino-acid N-terminal extension (the "Long"). Originally derived from porcine growth hormone sequence. This extension reduces IGFBP binding.
• An arginine substitution at position 3 (the "R3"). Arginine replaces the native glutamate. This substitution reduces carrier-protein binding affinity by orders of magnitude.

The combined effect is a peptide that circulates less bound, for longer, with more free receptor occupancy. A 2023 production study by Lu et al. demonstrated that LR3 matches the native form for cell-proliferation activity in in vitro assays. In animal models, the extended free fraction translates to sustained receptor signaling that is not attenuated by IGFBP sequestration.

Native version vs LR3 vs mecasermin

Three molecules in this family get confused. They aren't the same thing.

• Native version. The 70-amino-acid peptide produced endogenously by the liver. Over 95% is bound to carrier proteins in circulation.
• Mecasermin (Increlex). Recombinant native version, same 70-amino-acid sequence. FDA-approved in 2005 for severe pediatric deficiency. Dosed twice daily by injection. The only FDA-approved therapy in this family.
• LR3. The 83-residue engineered version with the front-end tail and the position-3 swap. Not FDA-approved. Sold as a research reagent.

The mecasermin prescribing information illustrates the safety profile of a controlled IGF-1-axis therapy. It carries warnings for intracranial pressure increases, slipped capital femoral epiphysis, and scoliosis — effects documented even in closely monitored pediatric study participants dosed twice daily with the heavily buffered native form. Active or suspected malignancy is listed as a contraindication, reflecting the cancer-biology concern discussed below.

What the 2020–2026 literature shows

The recent peer-reviewed record on LR3 is sparse and almost entirely in animals. Here are the four findings worth knowing:

Fetal heart growth in sheep (2020). Jonker and colleagues showed LR3 infusion grew new heart-muscle cells and increased fetal sheep heart mass with matching blood-vessel growth (Jonker et al., 2020). The result supports use in fetal-growth restriction. But fetal heart growth isn't the same as adult exercise adaptation, and the paper doesn't endorse chronic adult use.

Fetal pancreas defects (2021, 2023). Two White-group papers found that a one-week LR3 infusion in fetal sheep cut insulin output, with the defect lasting in isolated pancreatic islets (White et al., 2021). A 2023 follow-up showed a 90-minute exposure didn't cause a lasting defect (White et al., 2023). The authors flag concerns about long-term use. That concern applies with extra force to chronic adult muscle-growth use, where chronic exposure is the whole point.

Alzheimer's mouse model (2024). A seven-month nasal-spray LR3 study in 5XFAD male mice showed amyloid plaque shifts and better body composition. But the treatment failed to preserve cognitive function (Engel et al., 2024). The authors didn't support LR3 as an Alzheimer's monotherapy. This is the only recent chronic LR3 study in an adult-mouse disease model. Plaque biology shifted. Cognition didn't.

Human clinical evidence (and why there isn't any)

There are zero human RCTs of LR3 for muscle growth, body composition, anti-aging, recovery, or any other use in healthy adults during 2020–2026. No FDA IND on public record. No industry pipeline for any wellness or performance use.

The FDA-approved record in this family is entirely mecasermin (the native version) for severe pediatric deficiency. That's not the muscle-growth or anti-aging use LR3 is marketed for. Bodybuilding-community claims rest on extrapolation from the broader biology, not direct LR3 trial data. The biology is plausible. The trial data to back chronic adult use is what's missing.

GH-axis alternatives

Upstream secretagogues CJC-1295, ipamorelin FDA-approved (tesamorelin)

Peptriva does not stock IGF-1 LR3 — the cancer-axis concern at chronic adult administration is the reason. The upstream GH-axis catalog (CJC-1295, ipamorelin, tesamorelin) engages the GH/IGF-1 axis while preserving physiological negative-feedback regulation. Tesamorelin is the only FDA-approved peptide in this category. Research-grade reference compounds, COA per lot.

Browse the GH-axis catalog

The cancer-biology concern at the center

This growth-factor pathway is one of the most-studied in cancer biology. Higher circulating levels of the native hormone have been associated with increased risk of several cancers — breast, prostate, colorectal, and lung — in large long-term epidemiological studies. Signaling through this pathway activates proliferative programs (PI3K/AKT and MAPK/ERK), suppresses apoptosis, and promotes tumor angiogenesis.

Multiple companies have developed blockers of this pathway as oncology candidates — the investigational direction of the field is inhibition, not amplification.

Within that context, LR3 represents the most pro-mitogenic configuration of the pathway that pharmacology can produce. The endogenous form circulates 95%+ bound to carrier proteins. Mecasermin is dosed twice daily in closely monitored pediatric study participants precisely because that buffer limits free-fraction exposure. LR3 was engineered specifically to evade that physiological throttle — producing sustained, unbuffered receptor signaling that no endogenous state replicates.

To be precise: no human RCT quantifies the cancer risk of chronic adult LR3 administration. The concern is inferred from population data linking endogenous hormone levels to cancer incidence and from the pharmacology, which produces higher and more prolonged IGF-1R signaling than the native form. The FDA prescribing information for mecasermin lists active or suspected malignancy as a contraindication for the native, buffered form; LR3 amplifies the same signal.

Other risks worth naming

• Hypoglycemia. The IGF-1 axis has insulin-like receptor cross-reactivity; preclinical and mecasermin clinical data document the potential for significant blood glucose reductions, with risk compounded by concurrent insulin or oral hypoglycemic agents.
• Pancreatic islet defects from chronic exposure. A one-week LR3 infusion in fetal sheep produced lasting impairment in isolated pancreatic islets (White et al., 2021). Implications for chronic adult mammalian models remain uncharacterized.
• Acromegaly-spectrum effects. Sustained IGF-1R overactivation is mechanistically related to acromegalic pathology — soft-tissue overgrowth, skeletal changes, and cardiac hypertrophy.
• Pharmacodynamic interactions with insulin, oral hypoglycemics, growth hormone, and other GH-axis research compounds (CJC-1295, tesamorelin, ipamorelin) have been reported to compound metabolic effects.
• Identity and purity risk. LR3 is an 83-residue recombinant peptide requiring expression system production and correct disulfide folding. Grey-market material has no characterized purity or sequence confirmation.

Where LR3 sits relative to upstream GH-axis peptides

Our GH-axis overview covers the broader family. The relevant comparison for LR3 is to upstream releasers that nudge the body to make its own growth hormone through normal regulation:

• CJC-1295. A growth-hormone-releasing peptide. Triggers a natural GH pulse and natural hormone production, with the body's feedback loops still working.
• Ipamorelin. A selective ghrelin-pathway peptide. Releases pituitary GH without raising cortisol or prolactin.
• Tesamorelin. A stabilized GH-releasing peptide. FDA-approved for HIV-associated lipodystrophy. The only FDA-approved peptide in this category, with Phase III data behind its approved use.

The mechanistic contrast: upstream releasers preserve the natural GH pulse pattern and the endocrine feedback loops. LR3 bypasses that regulatory architecture entirely. Preservation of physiological feedback is associated with a more characterized safety profile than direct downstream receptor activation. For tissue-repair and GH-axis research, BPC-157 and tesamorelin represent more conservatively positioned pathways. Peptriva stocks both. Peptriva does not stock LR3.

Regulatory status and WADA

• FDA (US): Not approved for any use. The native version (mecasermin / Increlex) is approved for severe pediatric deficiency. LR3 is a different molecule and isn't approved.
• EMA (EU): Not approved.
• WADA: Explicitly prohibited under category S2.3 ("Growth factors and growth factor modulators"), both in-competition and out-of-competition. The WADA Prohibited List names this hormone and its analogs explicitly. One of the clearest prohibitions for any research peptide. Athletes face sanctions for documented use.
• Sale as a research reagent in the U.S. is legal when labeled for laboratory use only. Sale or marketing as a human therapy, with dosing instructions or efficacy claims, is illegal and draws FDA enforcement.

Pricing benchmarks for LR3 in 2026

LR3 pricing varies more widely than most peptides because making it correctly is hard. 83 residues with disulfide bonds. Recombinant production is preferred over chemical synthesis:

• 1 mg vial from a legitimate research-reagent supplier: $100–$250.
• 1 mg vial from a grey-market bodybuilding supplier: often $40–$80. That gap raises identity, purity, and contamination questions.

Correctly produced LR3 requires recombinant expression, correct disulfide folding, and identity confirmation via mass spectrometry showing the full 83-residue molecule. A CoA showing only generic native-hormone identity is insufficient for confirming the LR3 analog. Pricing substantially below the research-reagent floor is a recognized indicator of uncharacterized quality.

BPC-157 & tesamorelin

BPC-157 (tissue-repair research) Tesamorelin (FDA-approved GH-axis) ≥99% pure

Peptriva stocks BPC-157 (15-residue VEGFR2-active tissue-repair peptide) and tesamorelin (the only FDA-approved GH-axis peptide) as research-grade reference compounds for GH/IGF-1-axis and tissue-repair studies, without the IGF-1 LR3 cancer-biology concern. Both ship with batch-matched CoAs from ISO 17025 third-party labs.

See the catalog

Frequently asked questions

What is IGF-1 LR3?

A synthetic 83-amino-acid version of human insulin-like growth factor 1. Two modifications: a 13-residue front-end tail (the "Long") and an arginine swap at position 3 (the "R3"). Those changes drop the binding of carrier proteins that normally hold over 95% of the native hormone. The result is a longer-lasting peptide with much more free signal at its target. It's sold as a research reagent and is widely diverted to grey-market bodybuilding without any human RCT support.

LR3 vs the native version (mecasermin / Increlex)

Mecasermin is the 70-amino-acid native hormone, unmodified. It's FDA-approved for severe pediatric deficiency and dosed twice daily because the natural buffer makes the free fraction short-lived. LR3 was engineered specifically to dodge that buffer. Different sequences. Different pharmacology. Only mecasermin has FDA approval.

Is LR3 FDA-approved?

No. No FDA approval, no EMA approval, no approved use. Mecasermin (the native version) is the only FDA-approved therapy in this family, restricted to severe pediatric deficiency. LR3 is sold legally as a research reagent labeled for lab use only.

LR3 cancer risk: what's the concern?

Higher endogenous IGF-1 blood levels have been associated with increased cancer risk in population studies. Signaling on this pathway activates proliferative programs that malignant cells exploit. Chronic LR3 administration produces higher and more sustained IGF-1R signaling than any endogenous state. No RCT quantifies the cancer risk of chronic adult LR3 administration. The concern is inferred from population epidemiology plus LR3 pharmacology. The mecasermin FDA prescribing information contraindicates active or suspected malignancy for the native, buffered form; LR3 amplifies the same signaling axis.

LR3 WADA status

Explicitly prohibited under WADA category S2.3 (growth factors and growth-factor modulators). In-competition and out-of-competition. Athletes face sanctions for documented use.

How does LR3 compare to CJC-1295 / ipamorelin for GH-axis research?

CJC-1295 and ipamorelin act upstream: they stimulate pituitary GH release, which then drives hepatic IGF-1 production through the normal regulatory axis, with negative feedback preserved. LR3 bypasses that regulatory architecture and binds the IGF-1 receptor directly with reduced IGFBP buffering. Upstream secretagogues preserve more of the physiological regulatory machinery. Tesamorelin is the only FDA-approved compound in the upstream GH-axis category. The compounds represent different positions on the regulatory-preservation spectrum, each with its own risk profile.

How much does LR3 cost?

Research-reagent supplier pricing in 2026: $100–$250 per 1 mg vial. Grey-market bodybuilding pricing: often $40–$80 per 1 mg. The gap raises identity, purity, and contamination concerns for a peptide this hard to make correctly. We don't stock LR3.